Moreover, astragalus flavonoid, which is widely used in the clinical treatment of DN, has been shown to ameliorate podocyte scorching and injury under high glucose conditions by targeting METTL3 for m6A modification thereby mediating NLRP3 inflammasome activation and PTEN/PI3K/Akt signaling (Liu et al. 2021a). This evidence concerns the gene METTL3 and liver dysplastic nodule.